2017
Global Microbial Identification Market to witness a CAGR of 5.6% during 2017-2023
NEW YORK, Dec. 30, 2017 (GLOBE NEWSWIRE) -- The global microbial identification market is ...
Global Microbial Identification Market to witness a CAGR of 5.6% during 2017-2023
NEW YORK, Dec. 30, 2017 (GLOBE NEWSWIRE) -- The global microbial identification market is ...
Edge’s EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
BERKELEY HEIGHTS, N.J., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a ...
Edge’s EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
BERKELEY HEIGHTS, N.J., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a ...
Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook
HOUSTON, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company ...
Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook
HOUSTON, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company ...
Nutra Pharma Letter to Shareholders
CORAL SPRINGS, Fla., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC:NPHC), a ...
Nutra Pharma Letter to Shareholders
CORAL SPRINGS, Fla., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC:NPHC), a ...
Karolinska Development’s Chairman of the Board resigns from his position
STOCKHOLM, December 29, 2017. Karolinska Development announces today that the company's Chairman of the ...
Karolinska Development’s Chairman of the Board resigns from his position
STOCKHOLM, December 29, 2017. Karolinska Development announces today that the company's Chairman of the ...
Delcath Announces Exit from Convertible Note
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...
Delcath Announces Exit from Convertible Note
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology ...
